CLOS
MCRB icon

Compagnie Lombard Odier SCmA’s Seres Therapeutics MCRB Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-70
Closed -$14K – 799
2016
Q4 		$14K Hold
70
– – ﹤0.01% 731
2016
Q3 		$17K Hold
70
– – ﹤0.01% 802
2016
Q2 		$41K Hold
70
– – ﹤0.01% 693
2016
Q1 		$37K Hold
70
– – ﹤0.01% 758
2015
Q4 		$49K Buy
+70
New +$46K ﹤0.01% 695

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Compagnie Lombard Odier SCmA's MCRB Position: Q1 2017 in Review

Compagnie Lombard Odier SCmA sold out of Seres Therapeutics (MCRB) in Q1 2017, closing a stake of 70 shares — an estimated $14K sold.

Compagnie Lombard Odier SCmA first reported a position in MCRB in Q4 2015 and held it in 5 quarters. The position peaked at $49K in Q4 2015. 79 funds tracked by Wall St. Rank hold MCRB as of Q1 2017.

  • Compagnie Lombard Odier SCmA reported no remaining Seres Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 70 Seres Therapeutics shares in Q1 2017, an estimated $14K.
  • Compagnie Lombard Odier SCmA first reported a position in Seres Therapeutics in Q4 2015 and held it in 5 quarters.
  • Compagnie Lombard Odier SCmA's Seres Therapeutics position peaked at $49K in Q4 2015.
  • 79 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2017.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2017, filed 15 May 2017.